Oncternal Therapeutics (NASDAQ:ONCT) shares are trading higher on Tuesday after the company announced it received a pediatric disease designation from the FDA for its TK216 for the treatment of Ewing Sarcoma.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. Its product pipeline includes Cirmtuzumab, TK216, and ROR1 CAR-T.
Oncternal Therapeutics shares traded up 8.38% to $1.94 on Tuesday. The stock has a 52-week high of $6.29 and a 52-week low of $1.67.